A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

This publication has 26 references indexed in Scilit:

• Safety and Immunogenicity of UBI HIV-1_MNOctameric V3 Peptide Vaccine Administered by Subcutaneous Injection
  AIDS Research and Human Retroviruses, 1997
• Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1
  The Journal of Infectious Diseases, 1996
• A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide Vaccine
  The Journal of Infectious Diseases, 1996
• HIV vaccine development
  AIDS, 1996
• Human Studies in the Development of Human Immunodeficiency Virus Vaccines
  The Journal of Infectious Diseases, 1995
• Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers
  AIDS, 1995
• Multiepitope Polypeptide of the HIV-1 Envelope Induces Neutralizing Monoclonal Antibodies against V3 Loop
  AIDS Research and Human Retroviruses, 1994
• hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120
  AIDS, 1993
• Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody
  Nature, 1992
• Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
  Proceedings of the National Academy of Sciences, 1991